Bringing Care to Underserved and Vulnerable Patient Populations

Medical Care ◽  
2021 ◽  
Vol 60 (1) ◽  
pp. 1-2
Author(s):  
Kimiyoshi J. Kobayashi ◽  
Andrew S. Karson
Keyword(s):  
Vulnerable Patient

A Genomic Approach to Characterize the Vulnerable Patient – a Clinical Update

2019 ◽  
Vol 4 (3) ◽  
pp. 141-144
Author(s):  
Evelin Szabó ◽  
Zsolt Parajkó ◽  
Diana Opincariu ◽  
Monica Chițu ◽  
Nóra Raț ◽  
...  
Keyword(s):  
Risk Factors ◽  
Myocardial Ischemia ◽  
Treatment Options ◽  
Ischemic Heart ◽  
Pathophysiological Mechanism ◽  
Ischemia And Reperfusion Injury ◽  
Myocardial Ischemia And Reperfusion ◽  
Vulnerable Patient ◽  
Traditional Risk Factors ◽  
New Treatment

Abstract Atherosclerosis is the elemental precondition for any cardiovascular disease and the predominant cause of ischemic heart disease that often leads to myocardial infarction. Systemic risk factors play an important role in the starting and progression of atherosclerosis. The complexity of the disease is caused by its multifactorial origin. Besides the traditional risk factors, genetic predisposition is also a strong risk factor. Many studies have intensively researched cardioprotective drugs, which can relieve myocardial ischemia and reperfusion injury, thereby reducing infarct size. A better understanding of abnormal epigenetic pathways in the myocardial pathology may result in new treatment options. Individualized therapy based on genome sequencing is important for an effective future medical treatment. Studies based on multiomics help to better understand the pathophysiological mechanism of several diseases at a molecular level. Epigenomic, transcriptomic, proteomic, and metabolomic research may be essential in detecting the pathological phenotype of myocardial ischemia and ischemic heart failure.

scholarly journals Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan

2021 ◽  
pp. 1-6
Author(s):  
Philipp G. Hemmati ◽  
Dorothea Fischer ◽  
Frank Breywisch ◽  
Sabine Wohlfarth ◽  
Matthias Kramer ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Care Center ◽  
Tertiary Care ◽  
Cancer Center ◽  
Staff Members ◽  
Oncology Service ◽  
Containment Measures ◽  
Vulnerable Patient ◽  
Set Up ◽  
Oncology Unit

Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.

scholarly journals Neurofeedback Overtraining and the Vulnerable Patient

2008 ◽  
Vol 11 (3) ◽  
pp. 63-66 ◽  
Author(s):  
Thomas V. Matthews
Keyword(s):  
Vulnerable Patient

Children with Medical Complexity: Challenges and Opportunities for Human Factors/Ergonomics

2020 ◽  
Vol 64 (1) ◽  
pp. 697-701
Author(s):  
Hanna Barton ◽  
Ryan Coller ◽  
Sara Finesilver ◽  
Christopher Lunsford ◽  
Rupa S. Valdez ◽  
...  
Keyword(s):  
Human Factors ◽  
Family Caregivers ◽  
Family Caregiver ◽  
Children With Medical Complexity ◽  
Patient Journey ◽  
Medical Complexity ◽  
Challenges And Opportunities ◽  
Vulnerable Patient

For vulnerable patient populations, such as children with medical complexity (CMC), the patient journey is fraught with challenges. By providing a range of perspectives including clinicians, a family caregiver, and Human Factors/Ergonomics (HF/E) experts, the present panel will describe the unique opportunities for HF/E to design jointly optimized systems for CMC and their family caregivers, including an explication of some of the specific challenges and complexities related to studying the work of and designing systems for this population. We will also highlight the ways in which HF/E could help in the design of solutions to improve outcomes for families.

scholarly journals Preparing Medical Students to Address the Needs of Vulnerable Patient Populations: Implicit Bias Training in US Medical Schools

2020 ◽  
Vol 30 (1) ◽  
pp. 123-127 ◽  
Author(s):  
Matthew C. Morris ◽  
Robert Lyle Cooper ◽  
Aramandla Ramesh ◽  
Mohammad Tabatabai ◽  
Thomas A. Arcury ◽  
...  
Keyword(s):  
Medical Students ◽  
Implicit Bias ◽  
Medical Schools ◽  
Vulnerable Patient

scholarly journals Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

2020 ◽  
Vol 10 ◽  
pp. 204512532093757
Author(s):  
Shaina Musco ◽  
Vivian McAllister ◽  
Ian Caudle
Keyword(s):  
Dopamine Receptor ◽  
Blocking Agent ◽  
Population Based ◽  
Rational Approach ◽  
Receptor Blocking ◽  
Serotonergic Receptors ◽  
Vulnerable Patient ◽  
The Subject ◽  
Dopamine Signaling ◽  
The Brain

Dopamine-receptor blocking agent-associated akathisia (DRBA-A) is an adverse effect that can significantly limit the use of these important medications for the treatment of a variety of psychiatric diseases, yet there is no unifying theory regarding its pathophysiology. This knowledge gap limits clinicians’ ability to effectively manage DRBA-A and mitigate negative outcomes in an already vulnerable patient population. Based on a review of the current literature on the subject, it is hypothesized that dopaminergic and noradrenergic signaling is perturbed in DRBA-A. Accordingly, it is proposed that the optimal agent to manage this extrapyramidal symptom should increase dopamine signaling in the affected areas of the brain and counteract compensatory noradrenergic signaling via antagonism of adrenergic or serotonergic receptors.

scholarly journals Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1396 ◽  
Author(s):  
Sévérine de Bruijn ◽  
Sébastien Anguille ◽  
Joris Verlooy ◽  
Evelien L. Smits ◽  
Viggo F. van Tendeloo ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Pediatric Cancer ◽  
Cancer Vaccines ◽  
Pediatric Population ◽  
Cancer Recurrence ◽  
Western World ◽  
Cancer Treatments ◽  
Vaccination Strategies ◽  
Vulnerable Patient ◽  
Therapeutic Cancer Vaccines

Dendritic cell-based and other vaccination strategies that use the patient’s own immune system for the treatment of cancer are gaining momentum. Most studies of therapeutic cancer vaccination have been performed in adults. However, since cancer is one of the leading causes of death among children past infancy in the Western world, the hope is that this form of active specific immunotherapy can play an important role in the pediatric population as well. Since children have more vigorous and adaptable immune systems than adults, therapeutic cancer vaccines are expected to have a better chance of creating protective immunity and preventing cancer recurrence in pediatric patients. Moreover, in contrast to conventional cancer treatments such as chemotherapy, therapeutic cancer vaccines are designed to specifically target tumor cells and not healthy cells or tissues. This reduces the likelihood of side effects, which is an important asset in this vulnerable patient population. In this review, we present an overview of the different therapeutic cancer vaccines that have been studied in the pediatric population, with a main focus on dendritic cell-based strategies. In addition, new approaches that are currently being investigated in clinical trials are discussed to provide guidance for further improvement and optimization of pediatric cancer vaccines.

Sign in / Sign up

Export Citation Format

Share Document